Published: 4 June 2020
Publications
Recent approvals: new active ingredients or new indications
Prescriber Update 41(2): 34
June 2020
For the period 16 January 2020 to 15 April 2020.
Recent approvals of medicines with new active ingredients
| Trade name (Active ingredient) | Dose form and strength(s) | Therapeutic area |
|---|---|---|
| Aimovig (erenumab) | Solution for injection 70 mg/mL 70 mg/mL pen |
Migraine |
| Brintellix (vortioxetine) | Tablet 5 mg 10 mg 15 mg 20 mg |
Major depressive disorder |
| Fasenra (benralizumab) | Solution for injection 30 mg/mL |
Eosinophilic asthma |
| Lenvima (lenvatinib) | Capsule 4 mg 10 mg |
Thyroid cancer Renal cell carcinoma Hepatocellular carcinoma |
| Nitisinone DiPharma (nitisinone) | Capsule 2 mg 5 mg 10 mg |
Hereditary tyrosinemia type 1 (HT-1) |
| Oncaspar (pegaspargase) | Solution for injection 3750 U/5mL |
Acute lymphoblastic leukaemia |
Approved medicines with new indications
| Keytruda (pembrolizumab) | Powder for infusion 50 mg Concentrate for infusion 25 mg/mL |
Renal cell carcinoma |
| Praluent (alirocumab) | Solution for injection 75 mg/mL 150 mg/mL |
Prevention of cardiovascular events |
| Xgeva (denosumab) | Solution for injection 70 mg/mL |
Multiple myeloma Giant cell tumour of bone Hypercalcaemia of malignancy |
See the Medsafe website for
more information about these medicines.
Data sheets of currently
marketed medicines are also available.
